Scarica l'app Stockscreener
2.32
4.04%
0.09
Dopo l'orario di chiusura:
2.32
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - minichart.com.sg
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan
MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan
Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - tipranks.com
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan
Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan
Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - minichart.com.sg
Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView
Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Moleculin to Present at 38th Annual ROTH Conference - The Manila Times
Moleculin Biotech Inc expected to post a loss of $6.11 a shareEarnings Preview - TradingView
Net current asset value per share of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
Moleculin Reports Second Quarter 2024 Financial Results and Prov - GuruFocus
MBRX Should I Buy - Intellectia AI
Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com India
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - The Manila Times
Moleculin Biotech releases CEO update on leukemia trial - Investing.com
Moleculin Biotech (MBRX) seeks vote on 6.37M warrants and name change - Stock Titan
Maxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX) - The Globe and Mail
Pullback Watch: Will Moleculin Biotech Inc benefit from geopolitical trendsMarket Activity Report & Safe Capital Growth Tips - baoquankhu1.vn
Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow
Aug Reactions: Will Moleculin Biotech Inc benefit from geopolitical trends2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI
Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):